ATH's Principal Activity is the commercialise research into Parkinsonian movement disorders, Alzheimer's disease, Huntington disease and other neurodegenerative disorders.
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||-31.79%|
|vs ASX 200 (1yr)||-35.88%|
|Book Value Per Share||$0.01|
ATH is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.
Alterity Therapeutics Limited (ATH, formerly Prana Biotechnology Limited) is an Australian biotechnology company which focusses to commercialise research into Parkinsonian movement disorders, Alzheimer's disease, Huntington disease and other neurodegenerative disorders.
Incorporated in VIC on 11/11/1997 as Prana Corporation Pty Ltd. Incorporation status changed to "Limited" on 26/11/1999. Name changed to Prana Biotechnology Limited on 05/01/2000.
DPS and Yield calculations use the Pay Date.
|Dr David Stamler||Chief Executive Officer||Jan 2021|
|Mr Phillip Hains||Company Secretary||May 2014|
|Mr Lawrence Gozlan||Non-Executive Director||Aug 2011||
Mr Lawrence Gozlan
Mr Gozlan is the Chief Investment Officer and Founder of Scientia Capital, a investment fund which has focus in life sciences. Prior to this, Mr Gozlan was in charge for the biotechnology investment portfolio in Australia as the institutional biotechnology analyst at QIC ("the Queensland Investment Corporation"). He previously worked as the senior biotechnology analyst in the equities team at Foster Stockbroking Pty Ltd, and gained senior corporate finance experience advising life sciences companies at Deloitte. Mr Gozlan is currently direcor of number of private biotechnology companies in the USA.
|Mr Peter Ashley Marks||Non-Executive Director||Jul 2005||
Mr Peter Ashley Marks
Mr Marks for over 13 years until the end of August 2014 was a Director of Peregrine Corporate Ltd, an Australian-based investment banking and corporate advisory firm. Mr Marks was until 2016, a Director of Armadale Capital Plc, which has focus on natural resources projects based in Africa with its current investments being a gold exploration company in DRC and a coal briquetting operation in South Africa. Mr Marks is currently a Consultant at Henslow Pty Ltd, a corporate and capital markets advisory firm. Mr. Marks is also a nonexecutive director of Terragenic International Ltd, an unlisted public company and has develop a novel hydrogen fuel system. From September 1998 until March 2001, Mr Marks was working with KPMG Corporate Finance Ltd (Australia), where he rose to Director and was in charge for heading up the equity capital markets group in Melbourne. From January 1992 until July 1994, Mr. Marks served as Head of the Melbourne Companies Department at the ASX and was founding Director of Momentum Funds Management Pty Ltd, an Australian venture capital firm. From December 1990 until December 1991, Mr Marks served as Director of Corporate Finance at Burdett Buckeridge & Young Ltd in their Melbourne offices, from August 1988 until November 1990, he held senior corporate finance position at Barings Securities Ltd, and from July 1985 until July 1988, he served as an Associate Director of McIntosh Securities, now Merrill Lynch Australia. In his roles with these financial institutions, Mr Marks was in charge for advising a number of listed and unlisted companies on issues ranging from corporate and company structure, to valuation, business strategies, acquisitions and international opportunities.
|Mr Geoffrey Paul Kempler||Non-Executive Chairman,Non-Executive Director||Jun 2005||
Mr Geoffrey Paul Kempler
Non-Executive Chairman,Non-Executive Director
Mr Kempler has served as our Chief Executive Officer, and in June 2005 he again assumed the position of Chief Executive Officer. Mr Kempler has experience in investment and business development, has been in charge for the implementation of our strategic plan and the commercialisation of our technology.
|Mr Brian Derek Meltzer||Non-Executive Director||Dec 1999||
Mr Brian Derek Meltzer
Mr Meltzer spent 25 years in investment banking. His breadth of expertise includes property transactions, corporate advisory, corporate finance, management buyouts, venture capital and syndications. He has held a number of Board and Board Advisory roles for private companies in the human resources, health, aged care, software, entertainment and finance sectors, including Director of a federal government Innovation Investment Fund. Mr Meltzer is also a Director of the Australia-Israel Chamber of Commerce, Chairman of Independence Australia and Chairman of a privately owned corporate health and wellness business.
|David Stamler||Chief Executive Officer||N/A|
ATH directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
|18/09/20||Tristan Edwards||Issued||7,000,000||$0.054||$378,000||Issue of options|
|18/09/20||Peter Marks||Issued||7,000,000||$0.054||$378,000||Issue of options|
|18/09/20||Lawrence Gozlan||Issued||7,000,000||$0.054||$378,000||Issue of options|
|18/09/20||Geoffrey Kempler||Issued||14,000,000||$0.054||$756,000||Issue of options|
|18/09/20||David Sinclair||Issued||7,000,000||$0.054||$378,000||Issue of options|
|18/09/20||Brian Meltzer||Issued||7,000,000||$0.054||$378,000||Issue of options|
The current holdings of ATH directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.
Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.
|Name||Last Notice||Total Shares||Shares Held (%)|
|Life Biosciences LLC||18/03/2022||243,396,873||10.10|
|The Bank of New York Mellon Corporation||02/05/2022||1,422,723,388||59.11|
12 month transaction history compiled from ASX announcements.
|Date||Name||Bought||Previous %||New %|
|15-03-22||The Bank of New York Mellon Corporation||259,216,860||49.42||60.19|
|09-07-21||The Bank of New York Mellon Corporation||48,300,000||56.16||58.17|
|07-07-21||The Bank of New York Mellon Corporation||325,257,900||42.65||56.16|
|06-07-21||The Bank of New York Mellon Corporation||68,395,500||39.81||42.65|
|02-07-21||The Bank of New York Mellon Corporation||11,361,960||45.43||39.81|
|28-06-21||The Bank of New York Mellon Corporation||20,975,520||44.42||45.43|
12 month transaction history compiled from ASX announcements.
|Date||Name||Sold||Previous %||New %|
|02-05-22||The Bank of New York Mellon Corporation||25,891,740||60.2||59.11|
|18-03-22||Life Biosciences LLC||26,508,660||11.2||10.10|
|20-01-22||The Bank of New York Mellon Corporation||24,730,260||50.4||49.42|
|05-01-22||The Bank of New York Mellon Corporation||27,103,020||51.6||50.44|
|20-12-21||The Bank of New York Mellon Corporation||26,904,480||52.7||51.57|
|02-12-21||The Bank of New York Mellon Corporation||24,720,180||53.7||52.69|
|22-11-21||The Bank of New York Mellon Corporation||30,656,100||55.0||53.72|
|01-11-21||The Bank of New York Mellon Corporation||26,375,640||56.1||54.99|
|30-08-21||The Bank of New York Mellon Corporation||26,036,220||57.2||56.08|
|10-08-21||The Bank of New York Mellon Corporation||24,126,660||58.2||57.17|
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.